Dexcel Pharma Technologies Ltd.

www.dexcel.com

Formerly Perio Products, Dexxon

High-Tech Company

TECH VERTICALS

Biopharmaceuticals, Life Sciences, MedTech, Pharmaceuticals, Therapeutics

General Data

Sector	Biomed
Company Stage:	Revenue Growth
Established	1968
Number of Employees	464
Employees in Israel	383
Reg. Number:	abCDe

DESCRIPTION

Dexcel Pharma is an international specialty pharmaceutical company which focuses on the development, manufacturing and marketing of innovative prescription, generics and OTC pharmaceutical products. The company is strategically focused and targeted to the greatest market potential, offering innovative, proprietary technologies and original formulations that improve outcomes in a range of therapeutic specialties. An intelligent, flexible and streamlined company, the Group's strength lies in its ability to identify industry trends and opportunities and act on them in a timely manner.

TECHNOLOGY

Dexcel Pharma’s discovery and development is based on its 9 unique, proprietary, modified-release drug delivery technologies and 22 groups of patents. The company also develops, manufactures and markets a broad range of controlled-release and difficult-to-manufacture prescription and over-the-counter (OTC) generic products.

Products and Phases

Product	Phase
Microlet	FDA Approved CE Approved
Digestive Therapy
LORIVAN	FDA Approved CE Approved
Psychiatry Therapy
MICROPIRIN	FDA Approved CE Approved
Cardiovascular Therapy

ESTIMATED ANNUAL SALES

	TARGET MARKETS
	Private Pharmaceutical Consumers, Health Care Providers, Pharmaceutical Industry

	BUSINESS MODEL
	B2B

AFFILIATION

Account ID	Affiliation Type	Name	Parent Name	Status
A3CE5FF0-1F7A-E111-AC59-00155D32A403		Dexcel Pharma Technologies Ltd.
C530C35B-55F1-E811-80FA-0050569A1018	Spin-off	Clexio Biosciences Ltd.	Dexcel Pharma Technologies Ltd.

REMARKS

Date	Remark
20/09/2018	Dexcel Pharma invested in Cynapsus Therapeutics and Roivant Sciences

CONTACT INFO

Expand / Collapse All

Main Address: Or Akiva, Israel

Address	1 Dexcel St.
City	Or Akiva
Country	Israel
Zip	30600000

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Jerusalem, Israel

Address	21 Nahum Haftzai
City	Jerusalem
Country	Israel
Zip	9548402

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Yoqneam, Israel

Address	10 Hakidma St., Northern High-Tech Park
City	Yoqneam
Country	Israel
Zip	2069200

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Northampton, United Kingdom

Address	7 Sopwith Way, Drayton Fields, Daventry
City	Northampton
Country	United Kingdom
Zip	NN11 8PB

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Alzenau, Germany

Address	2 Carl-Zeiss-Straße
City	Alzenau
Country	Germany
Zip	D-63755

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title
Mr. Ilan Oren	Co-CEO
Mr. Uri Oren	Co-CEO
Mr. Yaron Erez	CFO
Mr. Ygal Seelenfreund	VP, International Sales & Marketing
Ran Kreshtino	VP, & GM Israel
Ms. Miri Peleg	CIO
Ms. Amit Rotem	VP, HR
Mr. Itamar Yaron-Enden	VP, Business Development
Ms. Tamar Galanty	VP, Head of Quality
Mr. Jonathan Grushka	VP, General Counsel
Mr. Dan Oren	Founder

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Executive Chairman	Founder, Dexcel
abC Defghij	Board Member	COO, Dexcel
abC Defghij	Board Member	Co-CEO, Dexcel

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

Jun. 01, 2019

Revenue Growth

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

R&D Grant

Jun. 01, 2018

Revenue Growth

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

	Non-Equity Assistance

Expand / Collapse All

Date

Stage

Remarks

Non-Equity Assistance

Jan. 01, 1988

Revenue Growth

Contributor	Type	Amount	Remarks
abC Defghij	Technology Transfer Company	abCDe

	PORTFOLIO COMPANIES

Current Portfolio Companies (5)

Company Name

Sector

Round/Deal Type

Date Announced

Investor Amount

Total Deal Amount

Remarks

BioLight

N/A

Sixth Public Offering

04/11/2012

$2m

$7.3m

BrainQ

Third Round	01/01/2024	N/A	N/A
Second Round	16/08/2021	N/A	$40m

ImmunAI

Biomed

Second Round	27/10/2021	N/A	$215m
First Round	11/02/2021	N/A	$60m

Roivant Sciences

Biomed

Fourth Round	13/11/2018	N/A	N/A
Seed	01/05/2014	N/A	N/A

Syremis

Biomed

First Round

18/12/2025

N/A

$165m

Exits (2)

Company Name	Exit Type	Date Announced	Amount	Remarks
abC Defghij	Acquired	22/08/2025	abCDe	Following the acquisition, Xylo become a wholly-owned subsidiary of L.I.A. Pure Capital and was delisted from Nasdaq.
abC Defghij	IPO	10/03/2006	abCDe	01/2021: Delisted from TASE, continuing to trade on NASDAQ

Last Updated:	abCDe
IVC Number:	abCDe